Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure metrics:
- Shares Purchased: 1,600,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 13, 2012.
- Price Range: Highest price paid was 1,424.5 pence per share; lowest price paid was 1,441.5 pence per share.
- Treasury Holdings (Settled): 513,015,427 shares (9.37% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,915,427 shares (10.44% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,959,454,081 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,600,000 shares on September 13, 2012. This transaction increased the company's treasury share holdings, raising the percentage of total voting rights held in treasury to 10.44% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares held in treasury (513,015,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.44% held in treasury including unsettled shares) for disclosure threshold assessments.
- Note the specific share price range paid (1,424.5 to 1,441.5 pence) for this specific repurchase tranche.
- Confirm that the 4,959,454,081 shares in issue (excluding treasury) is the correct denominator for shareholder notification requirements under FSA rules.